UTILIZING PREDICTIVE BIOMARKERS TO IMPROVE TREATMENT OUTCOMES IN PATIENTS WITH METASTATIC COLORECTAL CANCER (mCRC): RESULTS WITH CETUXIMAB PLUS FOLFIRI IN THE CRYSTAL TRIAL

被引：0
|
作者：
Rougier, P. [1 ]
Janciauskiene, R. [2 ]
Paramonov, V [3 ]
Shparyk, Y. [4 ]
Gustavsson, B. [5 ]
Wagnerova, M. [6 ]
Gorbunova, V [7 ]
Utracka-Hutka, B. [8 ]
Celik, I [9 ]
Van Cutsem, E. [10 ]
机构：
[1] Hop Ambroise Pare, Boulogne, France
[2] Kauno Med Univ Klin, Kaunas, Lithuania
[3] Cherkassy Oblasnoy Onkodispanser, Charkassy, Ukraine
[4] Lviv Oncol Med & Diagnost Ctr, Lvov, Ukraine
[5] Sahlgrens Univ Hosp, Gothenburg, Sweden
[6] Vychodoslovensky Onkol Ustav, Kosice, Slovakia
[7] RAMN, NN Blokhin Russian Canc Res Ctr, Moscow, Russia
[8] MSC Mem Canc Ctr, Gliwice, Poland
[9] Merck KGaA, Darmstadt, Germany
[10] Univ Hosp Gasthuisberg Leuven, Leuven, Belgium
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：15 / 15
页数：1
相关论文
共 50 条
  • [31] FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial
    Loupakis, Fotios
    Cremolini, Chiara
    Masi, Gianluca
    Lonardi, Sara
    Zagonel, Vittorina
    Trenta, Patrizia
    Tomasello, Gianluca
    Ronzoni, Monica
    Ciuffreda, Libero
    Zaniboni, Alberto
    Tonini, Giuseppe
    Buonadonna, Angela
    Valsuani, Chiara
    Chiara, Silvana
    Carlomagno, Chiara
    Boni, Corrado
    Marcucci, Lorenzo
    Boni, Luca
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [32] Safety and pharmacokinetics (PK) of AMG 706 with panitumumab plus FOLFIRI or FOLFOX for the treatment of patients (pts) with metastatic colorectal cancer (mCRC)
    Schwartzberg, L. S.
    Hurwitz, H.
    Stephenson, J., Jr.
    Kotasek, D.
    Goldstein, D.
    Tebbutt, N.
    McGreivy, J.
    Sun, Y.
    Yang, L.
    Burris, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of 800 patients in a randomized phase III trial (EPIC).
    Abubakr, Y.
    Eng, C.
    Wong, L.
    Pautret, V.
    Scheithauer, W.
    Maurel, J.
    Kroening, H.
    Lutz, M.
    Zubel, A.
    Sobrero, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 160S - 160S
  • [34] FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (mCRC): Analysis of patients with KRAS-mutated tumors in the randomized German AIO study KRK-0306
    Stintzing, S.
    Neumann, J.
    Jung, A.
    von Weikersthal, L. Fischer
    Decker, T.
    Vehling-Kaiser, U.
    Jaeger, E.
    Heintges, T.
    Stoll, C.
    Modest, D. P.
    Kirchner, T.
    Scheithauer, W.
    Heinemann, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [35] Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer: Nordic 8 results
    Pfeiffer, P.
    Glimelius, B.
    Winther, S.
    Qvortrup, C.
    Yilmaz, M.
    Berglund, A.
    Vistisen, K.
    Kersten, C.
    Liposits, G.
    Sorbye, H.
    ANNALS OF ONCOLOGY, 2019, 30 : 131 - 131
  • [36] Early tumor shrinkage and depth of response as predictors of favorable treatment outcomes in patients with metastatic colorectal cancer treated with FOLFOX/FOLFIRI plus cetuximab.
    Somashekhar, S. P.
    Rauthan, Amit
    Rajgopal, Ashwin K.
    Kumar, Rohit C.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [37] Randomized phase II study of duligotuzumab plus FOLFIRI versus cetuximab plus FOLFIRI in 2nd-line patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC)
    Hill, Andrew G.
    Findlay, Michael
    Burge, Matthew
    Jackson, Christopher
    Garcia Alfonso, Pilar
    Samuel, Leslie
    Ganju, Vinod
    Karthaus, Meinolf
    Amatu, Alessio
    Jeffery, Mark
    DiBartolomeo, Maria
    Bridgewater, John
    Coveler, Andrew
    Hidalgo, Manuel
    Kapp, Amy V.
    Sufan, Roxana
    McCall, Bruce
    Penuel, Elicia
    Pirzkall, Andrea
    Tabernero, Josep
    CANCER RESEARCH, 2015, 75
  • [38] Randomized trial comparing cetuximab plus XELIRI versus cetuximab plus XELOX as first line treatment of patients with metastatic colorectal cancer (mCRC): A study of the german AIO CRC study group
    Heinemann, V.
    von Weikersthal, L. Fischer
    Vehling-Kaiser, U.
    Stauch, M.
    Oruzio, D.
    Schulze, M.
    Hass, H. G.
    Weiss, J.
    Dietzfelbinger, H.
    Moosmann, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [39] Analysis of the randomized trial of the German AIO CRC study group: Cetuximab plus XELIRI versus cetuximab plus XELOX as first-line treatment for patients with metastatic colorectal cancer (mCRC)
    Stintzing, S.
    Jung, A.
    Vehling-Kaiser, U.
    Stauch, M.
    Hass, H.
    Dietzfelbinger, H.
    von Weikersthal, Fischer L.
    Moosmann, N.
    Kirchner, T.
    Heinemann, V
    ONKOLOGIE, 2010, 33 : 226 - 226
  • [40] FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
    Heinemann, Volker
    von Weikersthal, Ludwig Fischer
    Decker, Thomas
    Kiani, Alexander
    Vehling-Kaiser, Ursula
    Al-Batran, Salah-Eddin
    Heintges, Tobias
    Lerchenmueller, Christian
    Kahl, Christoph
    Seipelt, Gernot
    Kullmann, Frank
    Stauch, Martina
    Scheithauer, Werner
    Hielscher, Joerg
    Scholz, Michael
    Mueller, Sebastian
    Link, Hartmut
    Niederle, Norbert
    Rost, Andreas
    Hoeffkes, Heinz-Gert
    Moehler, Markus
    Lindig, Reinhard U.
    Modest, Dominik P.
    Rossius, Lisa
    Kirchner, Thomas
    Jung, Andreas
    Stintzing, Sebastian
    LANCET ONCOLOGY, 2014, 15 (10): : 1065 - 1075
12345